409 related articles for article (PubMed ID: 26418759)
1. Thrombotic thrombocytopenic purpura: from diagnosis to therapy.
Mariotte E; Veyradier A
Curr Opin Crit Care; 2015 Dec; 21(6):593-601. PubMed ID: 26418759
[TBL] [Abstract][Full Text] [Related]
2. Current insight into thrombotic thrombocytopenic purpura.
Verbeke L; Delforge M; Dierickx D
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
[TBL] [Abstract][Full Text] [Related]
3. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
4. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Coppo P; Veyradier A
Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
[TBL] [Abstract][Full Text] [Related]
5. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic thrombocytopenic purpura.
Joly BS; Coppo P; Veyradier A
Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
[TBL] [Abstract][Full Text] [Related]
7. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.
Cataland SR; Wu HM
Expert Opin Pharmacother; 2007 Mar; 8(4):437-44. PubMed ID: 17309338
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic thrombocytopenic purpura in children.
Loirat C; Coppo P; Veyradier A
Curr Opin Pediatr; 2013 Apr; 25(2):216-24. PubMed ID: 23422353
[TBL] [Abstract][Full Text] [Related]
9. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Sadler JE
Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
[TBL] [Abstract][Full Text] [Related]
10. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic thrombocytopenic purpura-what is new?
Shah N; Sarode R
J Clin Apher; 2013 Feb; 28(1):30-5. PubMed ID: 23420593
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review.
Harambat J; Lamireau D; Delmas Y; Ryman A; Llanas B; Brissaud O
Pediatr Crit Care Med; 2011 Mar; 12(2):e90-3. PubMed ID: 20625343
[TBL] [Abstract][Full Text] [Related]
13. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays.
McDonald V; Liesner R; Grainger J; Gattens M; Machin SJ; Scully M
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):245-50. PubMed ID: 20083997
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
Elliott MA; Heit JA; Pruthi RK; Gastineau DA; Winters JL; Hook CC
Eur J Haematol; 2009 Oct; 83(4):365-72. PubMed ID: 19508684
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
Shibagaki Y; Fujita T
Hypertens Res; 2005 Jan; 28(1):89-95. PubMed ID: 15969259
[TBL] [Abstract][Full Text] [Related]
17. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic thrombocytopenic purpura in pediatric patients.
Steele M; Chen HH; Steele J; Chan AK; Lau KK
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Nov; 14(11):803-10. PubMed ID: 23146723
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.
Froissart A; Veyradier A; Hié M; Benhamou Y; Coppo P;
Eur J Intern Med; 2015 Nov; 26(9):659-65. PubMed ID: 26293834
[TBL] [Abstract][Full Text] [Related]
20. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
Bentley MJ; Wilson AR; Rodgers GM
Vox Sang; 2013 Nov; 105(4):313-8. PubMed ID: 23662653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
